TLDR
One small but well-designed human trial found that 1 g/day of a specific spirulina extract improved visual memory in older adults with mild cognitive impairment after 12 weeks. The rest of the evidence is animal and mechanistic.
- In a 2022 randomized trial of 80 adults with mild cognitive impairment, visual learning scores improved significantly in the spirulina group (p = 0.007). Verbal memory, plasma BDNF, and plasma amyloid-β did not change.
- In a 2024 mouse model of Alzheimer's disease, oral spirulina prevented memory deficits across four cognitive domains while reducing brain oxidative stress and inhibiting the same enzyme that prescription Alzheimer's drugs target.
- No evidence yet supports spirulina for memory in healthy aging adults. Every human study has used clinical populations.
Read on for the specific findings, the limits, and why the format of spirulina you take might matter more than the dose.
What does the research actually say about spirulina and memory?
The honest answer starts with one study.
In 2022, a research team at Jeonbuk National University Hospital in Korea ran the first randomized controlled trial testing spirulina extract on memory in older adults with mild cognitive impairment (Choi et al. 2022). Eighty volunteers, average age 68, randomized double-blind to either 1 g per day of a specific spirulina extract or matched placebo. Twelve weeks of supplementation. Mild cognitive impairment, or MCI, is the in-between phase that often precedes Alzheimer's disease, and it's the population where small interventions can show measurable effects.
Two memory outcomes moved. Visual learning improved significantly (p = 0.007). Visual working memory also improved (p = 0.024). On a separate cognitive screening test, vocabulary scores rose modestly (p = 0.043).
Several other outcomes did not move. Verbal memory was unchanged. Plasma BDNF, the brain-growth factor that's often invoked in spirulina marketing, did not change. Plasma amyloid-β, the protein associated with Alzheimer's pathology, also did not change. Total antioxidant capacity trended upward but missed statistical significance.
That mixed result is the most accurate picture of where the human evidence stands. Spirulina did something for these patients. It didn't do everything its mechanism story would predict.
This is the entire base of direct human evidence for spirulina and cognitive aging. No replication trial yet. No data in healthy older adults seeking prevention. No long-term follow-up.
Why is the human research so thin?
Spirulina occupies an awkward category. It's not a pharmaceutical, so the pharma trial infrastructure doesn't fund it. It's not a patented compound, so commercial sponsors have weak incentives. It's also been a known food in Mexico and Chad for centuries, which gives it the "ancient, trusted" framing that paradoxically reduces urgency to study it in modern populations.
The modern science is also younger than the marketing suggests. A Belgian botanist named Pierre Dangeard first wrote scientifically about spirulina consumption in 1940. Jean Léonard, a French botanist, formally identified the algae as a food source in 1965. Commercial production didn't start until the 1970s. The cognitive-research literature took another 50 years to produce its first randomized trial in humans.
The corpus that does exist clusters in animal and cell models. Two recent reviews summarize this gap honestly. A 2021 scoping review concluded that preclinical evidence is consistent and promising, but clinical trials remain preliminary (Sorrenti et al. 2021). A 2022 review found similar patterns in models of Alzheimer's, Parkinson's, and Multiple Sclerosis, but reviewed no human trials at all (Trotta et al. 2022).
That's the state of play. One human RCT. Several reviews acknowledging the gap. A growing body of mechanistic work in mice and cells.
How might spirulina affect the brain at a mechanistic level?
This is where the corpus gets denser. The mechanism story is built on three converging lines of evidence.
The first is antioxidant action in brain tissue. In 2024, researchers ran an experiment in mice given an intracerebroventricular injection of streptozotocin, a model that mimics the insulin signaling failure and oxidative stress of sporadic Alzheimer's disease (Tavares et al. 2024). Oral spirulina extract at 100 mg per kg for 16 days reduced lipid peroxidation, restored glutathione (the brain's main antioxidant), and reduced superoxide accumulation in both the prefrontal cortex and the hippocampus. These are the brain regions most involved in working memory and learning.
The second is reduced neuroinflammation. The same Tavares study tracked microglia and astrocyte activation, two cell types that release inflammatory signals when triggered. Spirulina treatment reduced activation of both in every brain region measured. This matters because chronic low-grade brain inflammation is now considered a central driver of cognitive aging, sometimes called inflammaging. Recent human work supports this mechanism translating across tissues: a 2025 triple-blind RCT in 80 adults with multiple sclerosis found that 1 g per day of spirulina for 12 weeks significantly reduced IL-1β and IL-6, two central inflammaging cytokines (Karimi et al. 2025). MS is not Alzheimer's, but the inflammatory pathway is shared.
The third is acetylcholinesterase inhibition. The Tavares study found that spirulina reduced AChE activity in the prefrontal cortex to control levels. Two earlier studies from a Korean research group nailed down the mechanism in different ways. One showed that a spirulina extract activated BDNF and CREB signaling in mouse hippocampal cells while suppressing AChE activity (Koh et al. 2017a). A second showed that the same extract reversed memory deficits in mice given amyloid-β injections, working through the BDNF/PI3K/Akt pathway to inhibit GSK-3β phosphorylation, a key enzyme implicated in Alzheimer's-type tau pathology (Koh et al. 2017b).
There's a lay analogy worth carrying. Acetylcholinesterase is the same enzyme that prescription Alzheimer's drugs like donepezil target. Spirulina extract appears to inhibit it too, though much more weakly. The mechanism isn't novel. Spirulina is hitting an established drug target through a food-derived compound. That's both interesting and very different from a treatment claim.
A separate line of work points at something even more fundamental. A 2024 study in yeast found that phycocyanin, spirulina's blue pigment, kept 75% of cells viable at day 14 of a chronological aging assay, compared with 26% in untreated controls (Nova et al. 2024). The proposed mechanism is hormesis: small, controlled stress signals trigger cellular repair and adaptation. The same logic explains why exercise, fasting, and mild cold exposure are linked to longevity in humans. If phycocyanin works through hormesis, it places spirulina in the same conceptual family as those interventions. Yeast is a long way from a human brain, so this is a candidate mechanism, not a confirmed one.
What does this evidence NOT support?
It's tempting to read the mechanism story above and conclude that spirulina prevents Alzheimer's disease. The science doesn't actually say that.
The Choi 2022 trial studied older adults who already had mild cognitive impairment. The improvement was on specific tests of visual memory and vocabulary. We cannot extrapolate that to healthy adults seeking cognitive enhancement, because the trial did not include healthy adults. We also cannot conclude that spirulina prevents progression from MCI to dementia, because the trial wasn't long enough to measure that.
The animal mechanism studies are stronger but still animal mechanism studies. The Tavares paper specifically notes a methodological caveat: spirulina was given starting 2 hours after the chemical insult, which means the study can't fully separate "spirulina rescued cognition" from "spirulina blocked the insult itself." The authors are honest about this. Anyone citing the paper should be too.
And one specific framing error has propagated through the popular coverage and even into one of the primary papers: spirulina is not "FDA approved" for any health use. The FDA grants Generally Recognized As Safe status to spirulina for food applications, which is a different legal category. The FDA does not approve supplements. We mention this because it appears in marketing copy and even in the conclusion of one peer-reviewed paper.
Fresh vs dried spirulina for brain compounds: does format matter?
For most spirulina health claims, format is a moderate variable. For brain-relevant compounds, it's a more important one.
Two of spirulina's most-studied bioactive components, phycocyanin and the long-chain omega-3 fatty acids, are heat-sensitive. Phycocyanin specifically degrades at the temperatures used in typical commercial drying. The standard processing pipeline for spirulina powder involves spray-drying at temperatures that reduce phycocyanin content and damage its three-dimensional structure. Even when the powder is sold as "high phycocyanin," standard tests don't always tell the active form from the broken-down form.
Fresh frozen spirulina skips the heat step entirely. The biomass is frozen at harvest and stays cold through distribution. The result is more intact phycocyanin and more of the omega-3 fatty acids that researchers credit for part of spirulina's anti-inflammatory profile (Karimi et al. 2025). For a compound class that has to make its way to the brain, where the blood-brain barrier limits what can pass through, intact bioactive structure matters.
The taste difference is the secondary advantage. Powder is fishy and earthy, which makes meaningful daily intake hard. Fresh frozen is closer to neutral, which makes a 5-gram daily serving feasible without a smoothie strong enough to mask it. The transparency angle matters too. At New Farmers we farm and freeze our own spirulina, with third-party testing for heavy metals and microcystin. That kind of supply-chain visibility is harder to find when spirulina passes through large international processors.
Who is the cognitive-aging evidence actually for?
The current evidence supports three different actions, depending on who's reading it.
People with mild cognitive impairment or a family history that worries them have the most direct evidence to act on. The Choi trial showed measurable visual memory improvement at 1 g per day over 12 weeks, with no notable adverse events. That's a reasonable interventional target. The evidence is small but the safety profile is strong.
People in the longevity-research community have indirect evidence to consider. The hormesis mechanism, the anti-inflammatory translation in humans, and the AChE pathway place spirulina in conversation with the broader interventions that crowd talks about: caloric restriction mimetics, mild oxidative-stress signals, anti-inflammaging compounds. None of this is proof. That puts daily spirulina in the same category as fish oil or vitamin D. The direct evidence for any specific outcome is weak. The mechanism is real. The downside is low.
Healthy adults seeking nootropic-style cognitive enhancement have the weakest case. Zero direct evidence supports that use. Anyone promising sharper thinking, better focus, or improved mood from spirulina in a healthy young or middle-aged adult is selling beyond the data.
What's missing from the cognitive-aging evidence base?
Five gaps stand out. We list them because we think readers deserve to know what the science doesn't yet show.
Longer human trials. Twelve weeks is short for cognitive endpoints. Disease progression in MCI is measured in years.
Trials in healthy aging adults. Every human study on cognitive endpoints has used a clinical population. Whether spirulina has measurable effects in cognitively normal 60-year-olds is an open question.
Replication of Choi 2022 outside Korea. A single-center trial in one population isn't a sturdy foundation for global recommendations.
Standardized extract definitions. The Choi trial used a specific 70% ethanol extract with defined chlorophyll content. The Tavares trial used an aqueous extract. Most consumer spirulina is whole-cell powder or fresh frozen. These are not interchangeable in research terms, and head-to-head comparisons don't exist.
Long-term safety data in cognitive populations. Spirulina has a strong general safety record over centuries of food use, but specifically in older adults taking it daily for years, the data is thin.
A 2026 trial in Food Science & Nutrition tested spirulina supplementation on cognitive function in patients undergoing methadone therapy (Asadolah-poor-kashi et al. 2026). It's worth tracking as the next human data point.
Frequently asked questions
Does spirulina actually improve memory?
In one specific population, yes. A 2022 RCT in older adults with mild cognitive impairment showed improvement in visual memory tests after 12 weeks of 1 g per day spirulina extract (Choi et al. 2022). Outside that population, the evidence is preclinical. Healthy adults seeking cognitive enhancement have no clinical evidence to act on.
Has spirulina been tested for Alzheimer's disease?
Not directly as a treatment in humans. Mouse models of Alzheimer's-like pathology show that spirulina extract can rescue memory deficits and reduce brain inflammation (Tavares et al. 2024). The same studies identify mechanisms (acetylcholinesterase inhibition, BDNF activation) that overlap with how prescription Alzheimer's drugs work, but at much weaker doses. No human Alzheimer's trial has been conducted.
How does spirulina work in the brain?
Three converging mechanisms have research support: reduction of brain oxidative stress, suppression of inflammatory glial cell activation, and inhibition of acetylcholinesterase (the same enzyme targeted by drugs like donepezil). Phycocyanin, spirulina's blue pigment, appears to be the most active compound. The evidence is strongest in animal and cell models; mechanism translation to humans is still being established.
Is there enough research on spirulina and brain health?
Not yet. The corpus is dense in animal and mechanism work but has only one direct human RCT on cognitive outcomes. Two recent narrative reviews (Sorrenti et al. 2021; Trotta et al. 2022) acknowledge this gap. More human trials are needed.
References
- Choi W-Y, Lee W-K, Kim T-H, et al. (2022). The Effects of Spirulina maxima Extract on Memory Improvement in Those with Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. https://doi.org/10.3390/nu14183714
- Sorrenti V, Castagna DA, Fortinguerra S, et al. (2021). Spirulina Microalgae and Brain Health: A Scoping Review of Experimental and Clinical Evidence. Marine Drugs. https://doi.org/10.3390/md19060293
- Trotta T, Porro C, Cianciulli A, Panaro MA. (2022). Beneficial Effects of Spirulina Consumption on Brain Health. Nutrients. https://doi.org/10.3390/nu14030676
- Tavares J, Oliveira AV, Nascimento TS, et al. (2024). Aqueous extract of Spirulina exerts neuroprotection in an experimental model of Alzheimer sporadic disease in mice induced by Streptozotocin. Metabolic Brain Disease. https://doi.org/10.1007/s11011-024-01477-7
- Karimi S, Shaygannejad V, Mohammadalipour A, et al. (2025). Effects of spirulina (Arthrospira) platensis supplementation on inflammation, physical and mental quality of life, and anthropometric measures in patients with relapsing-remitting multiple sclerosis (RRMS): a triple-blinded, randomized, placebo-controlled trial. Nutrition Journal. https://doi.org/10.1186/s12937-025-01200-x
- Koh E-J, Seo Y-J, Choi J, et al. (2017). Spirulina maxima Extract Prevents Neurotoxicity via Promoting Activation of BDNF/CREB Signaling Pathways in Neuronal Cells and Mice. Molecules. https://doi.org/10.3390/molecules22081363
- Koh E-J, Kim K-J, Song J-H, et al. (2017). Spirulina maxima Extract Ameliorates Learning and Memory Impairments via Inhibiting GSK-3β Phosphorylation Induced by Intracerebroventricular Injection of Amyloid-β 1-42 in Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18112401
- Nova M, Citterio S, Martegani E, Colombo S. (2024). Unraveling the Anti-Aging Properties of Phycocyanin from the Cyanobacterium Spirulina (Arthrospira platensis). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084215
- Asadolah-poor-kashi et al. (2026). The Efficacy of Spirulina on Cognitive Function, Psychological and Clinical Indicators in Men Patients Under Methadone Therapy: a Randomized Trial. Food Science & Nutrition. https://doi.org/10.1002/fsn3.71521